Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC — Stella

Home/Metastatic Castration-resistant Prostate Cancer/Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Castration-resistant Prostate Cancer trials

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Netherlands

Erasmus MC Cancer Institute, Rotterdam

Key details

Phase

Safety & dosing

Sponsor

Erasmus Medical Center

Enrollment target

~245 participants

Started

November 2023

Primary completion

May 2027

Age range

18 Years and older

Sex

Male only

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.